EuroBiotech: More Articles of Note


> Destiny Pharma filed for an IPO on London’s AIM. The antimicrobial biotech hired a CEO with IPO experience in April. And has now tapped into that experience to put together an offering to fund its lead candidate up to the start of a pivotal phase 3 program. Statement

> Merck Ventures invested in Macrophage Pharma. The VC offshoot of Merck KGaA added to the £9 million Macrophage raised from investors including Novo Holdings A/S in January. Fueled by the additional cash, Macrophage is now aiming to wrap up a clinical trial using the series A, an advance on its earlier aspiration to get to the end of preclinical development. Release

> Orchard Therapeutics’ gene therapy picked up a promising innovative medicine designation in the United Kingdom. The status is the first step on a pathway that could result in patients in the U.K. gaining early access to the treatment for “bubble boy” disease. Statement


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Ablynx put partnering plans for vobarilizumab on hold. AbbVie turned down the chance to license the phase 3-ready rheumatoid arthritis drug last year, prompting Ablynx to start looking for a new partner. Now, Ablynx has put the search on ice until after it posts data on the drug in systemic lupus erythematosus in the first half of next year. Release    

> Boehringer Ingelheim began a phase 2a NASH trial. Statement

> AC Immune talked up new additions to its preclinical neurodegenerative pipeline. Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.